Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Promising Pipeline | Fate Therapeutics' FT819 and FT522 show encouraging results in treating SLE and B-cell lymphoma, potentially revolutionizing autoimmune disease therapy |
Financial Challenges | Despite strong clinical data, Fate operates at a loss with negative EPS projections, balancing a $330.5M cash reserve against ongoing R&D expenses |
Market Outlook | Analyst price targets range from $2 to $10, reflecting varied optimism about Fate's future. The biotech sector's positive outlook may favor growth |
Strategic Potential | Successful trials could position Fate as a leader in cellular therapies, attracting partnerships and expanding market opportunities in cancer and autoimmune diseases |
Metrics to compare | FATE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFATEPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −2.1x | −0.5x | |
PEG Ratio | −0.05 | −0.09 | 0.00 | |
Price/Book | 0.5x | 0.8x | 2.6x | |
Price / LTM Sales | 14.2x | 7.9x | 3.3x | |
Upside (Analyst Target) | 316.7% | 318.2% | 38.9% | |
Fair Value Upside | Unlock | 40.1% | 5.4% | Unlock |